The U.S. FDA granted 510(k) clearance to Distalmotion SA's Dexter, its surgical robotic system, for use in cholecystectomy in ...

Researchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new ...

Developing a therapy for an ultra-rare condition has its challenges, including finding enough patients for clinical enrollment and convincing regulatory authorities that limited data prove the ...

Glycoengineering specialist Glycoera AG is preparing to take its extracellular protein degrader constructs into the clinic in the treatment of autoimmune diseases, after closing a $130 million series ...

EBR Systems Inc. raised AU$55.9 million (US$36 million) to commercialize its Wise cardiac resynchronization therapy system ...

Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate ...

The doctrine of inherent disclosure is not one of the more common methods for invalidating patent claims, but this doctrine ...

The variety of blood cells decreases with age. Some are lost, while others become dominant, leading to a loss of functional ...

The U.S. Trade Representative (USTR) is asking for help in its search for “freeloaders” that refuse to shoulder their share of the cost of biopharma R&D.

After reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences ...

GSK plc knew a good thing when it swooped in nearly three years ago to rescue Spero Therapeutics Inc.’s oral antibiotic from a complete response letter (CRL). New pivotal phase III study data showed ...

University of Health Sciences and Pharmacy in St. Louis has described estrogen-related receptor α (ERR) modulators reported to be useful for the treatment of diabetes, amyotrophic lateral sclerosis, ...